Abstract: Provided is a pharmaceutical composition including a supernatant of a culture medium that has been used for maintenance culture of stem cells in an undifferentiated state. The stem cells for the pharmaceutical composition may be pluripotent stem cells.

Abstract: The present disclosure provides a micron fish oil composition and a method for preparing the micron fish oil composition. The method includes mixing a composite plant colloid with a fish oil and subjecting to an emulsification treatment to obtain an emulsion; and homogenizing the emulsion at a pressure of 300 bar to 350 bar to obtain the micron fish oil composition. The present disclosure also provides a method for enhancing bioabsorbability and bioavailability in a subject, including administering to the subject in need thereof a food product including an effective amount of the micron fish oil composition.

Abstract: Disclosed herein is an avirulent live vaccine that involves a recombinant protozoan from the order Trypanosomatida having a knocked out or silenced cyclophilin gene, wherein the cyclophilin gene comprises T. cruzi cyclophilin 19 (TcCyp19) gene, or an orthologue thereof. Also disclosed is a method or inducing a protective immune response in a subject that involves administering to the subject a vaccine disclosed herein. Also disclosed is a method of treating or preventing Chagas disease, African trypanosomiasis, and/or leishmaniasis in a subject that involves administering to the subject a vaccine disclosed herein.

Abstract: The present disclosure relates to compositions and methods for modulating a transsynaptic signal through a neuroepithelial circuit between a gut sensory cell and the brain, as well as methods that involve modulating a transsynaptic signal through a neuroepithelial circuit between a gut sensory cell and the brain.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing brain injury.

Abstract: The present disclosure provides human fecal microbiota compositions, including fresh, frozen, and lyophilized compositions, for the treatment of disorders associated with dysfunctional microbiota, such as recurrent Clostridium difficile infection. In particular, the fecal microbiota composition comprises a cryoprotectant sugar, such as mannitol.

Abstract: The diatheses of animals vary depending on genetic backgrounds of the animals, and the microbial structure of an enterobacterial flora inherent in a host and the behavior of the concentration of a biological molecule sometimes vary depending on the diathesis of the host. In this case, it is needed to administer a proper probiotic. Provided is a microbial preparation for controlling the proportion of the population of bacteria belonging to the division Bacteroidetes, Firmicutes or Proteobacteria or the proportion of the population of bacteria belonging to the genus Clostridium, Lactobacillus, Bifidobacterium or Bacteroidetes in the enterobacterial florae in an animal body, and for controlling the concentration of a functional molecule contained in a living body, said microbial preparation containing a microorganism P01931 (International Accession No. BP-1931) MK-01A (International Accession No. BP-02066) or MK-03A (International Accession No. BP-02067) or a component of the microorganism.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing cancer.

Abstract: The invention relates to prevention of insulin resistance or low-grade chronic inflammation later in life upon ingestion of synbiotics early in life.

Abstract: Disclosed herein are methods and compositions related to probiotic formulas. These formulas comprise the bacterial strain Lactobacillus crispatus WZ-12 or a derivative thereof. Other strains which can be included in the composition include, but are not limited to, Lactobacillus salivarius 1-14, or Lactobacillus reuteri 2-2, and derivatives thereof. These compositions can be used in a variety of methods to treat and/or ameliorate diseases, such as colonization of antibiotic-resistant bacteria in the host organism. Also disclosed herein are methods of treating those subjects in need thereof by administering the compositions disclosed herein.

Abstract: The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of tumor-suppressive microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.

Abstract: Disclosed is a composition comprising a Sargassum horneri extract for alleviating lung injury or respiratory disease.

Abstract: The present invention relates to the preparation of a liquid fermentate of Sanghuangporus or an extract of Sanghuangporus, compounds identified from the liquid fermentate or the extract, and their novel activity.

Abstract: Disclosed is a method for preparing bitter Ganoderma lucidum spore powder, and relates to the field of drugs or health care products. The method includes: removing visible impurities from Ganoderma lucidum spores, conducting ice bath and heating extraction, filtering through a microfiltration membrane, sterilizing by drying, and conducting sporoderm disruption to obtain the bitter Ganoderma lucidum spore powder. The preparation method effectively improves the content of the bitter substances in the Ganoderma lucidum spore powder by removing shriveled spores through multiple times of impurity removal and filtration in combination with the manner of conducting sporoderm disruption after extraction. Taking the total Ganoderma lucidum triterpenoids in the Ganoderma lucidum spores as a representative of the bitter substances, the content of the total Ganoderma lucidum triterpenoids can reach 5-8%. Meanwhile, the preparation method can also make the content of Ganoderma lucidum polysaccharides reaching 6-10%.

Abstract: The problem to be solved is to suppress an elevation of blood glucose level by suppressing decomposition and absorption of a carbohydrate in the body; and further prevent or improve diabetes and obesity derived from hyperglycemic symptoms and chronic hyperglycemia, for a long time. To attain the object, an agent for suppressing ?-glucosidase activity and an agent for suppressing glucose absorption containing an amber extract as an active ingredient were invented.

Abstract: Provided herein are tumor-antigen VCX/Y specific peptides and engineered VCX/Y specific T cell receptors. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer. In addition, the VCX/Y-specific peptides may be used as a vaccine.

Abstract: A composition for the prevention and/or improvement of dry eye syndrome, dryness of eye and/or stiff neck and shoulder, which contains bilberry fruit extract and is effective with less intake. As one aspect of the present invention, the composition for the prevention or improvement of dry eye syndrome or dryness of eye contains a freeze-dried bilberry fruit extract. As another aspect of the present invention, the composition for the prevention or improvement of stiff neck and shoulder contains a freeze-dried bilberry fruit extract. As another aspect of the present invention, a composition for the prevention or improvement of dry eye syndrome, dryness of eye, and stiff neck and shoulder, contains a freeze-dried bilberry fruit extract.

Abstract: A refined Indigo Naturalis extract or Indigo-producing plant extract containing at least 65% (w/w) an indirubin derivative based on total weight of active ingredients is described. Also described are a pharmaceutical composition containing the refined extract, and the use of the pharmaceutical composition for treating or alleviating a disease or condition.

Abstract: The Take4B4 drink contains phytochemicals which is found in onions along with Vitamin C to help improve immunity. Onions is said to help reduce inflammation and heal infections. Raw onions lower the production of bad cholesterol (LDL). A powerful compound called quercetin in onions is known to play a significant role in preventing cancer. Lemons—the acid in lemons helps to neutralize free radicals linked to aging and most types of disease. The citric acid in lemon juice helps to dissolve gallstones, calcium deposits, and kidney stones. Lemons are rich in vitamin C and flavonoids that work against infections like the flu and colds. Soothing Triple Gel Thirst Quencher, the Aloe Vera contains Vitamin C, and other Vitamin and minerals. Okra contains Vitamin C and calcium. Lemons naturally have Vitamin C, and the Nopal Cactus contains anti-inflammatory agents. Nopal Cactus—said to control diabetes, is an anti-inflammatory agent, help improve sleep.

Abstract: The present invention discloses a composition for preparing a pain relieving drug, which includes poplar bark, Ligusticum wallichii, curcumin, ambergris, processed Radix Aconiti Lateralis, ray cartilage extract, wild ginseng, fructus psoraleae, garden balsam stem, pratt mountainash root-bark, annona muricata, Arisaema heterophyllum Blume, resina draconis, frankincense, myrrh, Brazilian sapodilla and camphor. The composition can be added with an appropriate auxiliary material to be made into dosage forms suitable for oral administration or external use, such as oral liquid, a patch, a liniment, a sustained-release agent and the like.

Abstract: A method for alleviating hair loss includes using a health supplement food prepared by mixing dried powders that include 5 to 15% by weight of black beans, 5 to 15% by weight of black sesame seeds, 5 to 15% by weight of corn, 5 to 15% by weight of adlay, 5 to 15% by weight of sorghum, 5 to 15% by weight of mulberry leaves, 5 to 15% by weight of mulberry fruits, 7 to 20% by weight of Polygonum multiflorum Thunberg, 5 to 15% by weight of dandelion, 1 to 10% by weight of licorice, 2 to 15% by weight of kelp, and 5 to 15% by weight of cactus based on solid content. The health supplement food may promote hair growth, alleviate and mitigate hair loss, regulate blood glucose, or alleviate and relieve gastric disorder symptoms.

Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.

Abstract: Provided herein are methods and compositions for treating subjects with Celiac disease.

Abstract: The disclosure relates to compositions having a high concentration of iturinic lipopeptides. In particular, the compositions have an iturinic lipopeptide concentration of between 20 and 150 g/l; they are stable and homogeneous as a result of the presence of surfactants.

Abstract: The present invention relates to the ophthalmic composition comprising from about 0.03% to about 2% by weight of cyclosporine, from about 0.05% to about 5% by weight of tamarind seed polysaccharide and a pharmaceutically acceptable carrier. Further the invention relates to the process for preparation of ophthalmic compositions and its use for the treatment of dry eye.

Abstract: The present invention relates to compositions and methods for modulating immune responses using at least one CRACC composition comprising an adenoviral vector comprising at least one CRACC fusion. Such CRACC compositions may be combined with a number of other therapeutic agents which target modulating immune responses, as well as, treatments that include immune events.

Abstract: The present invention relates to a use of cellular repressor of E1A-stimulated genes (CREG) protein, and in particular to a use of a CREG protein or an active fragment thereof in manufacture of a medicament for the prevention and/or treatment of a fatty liver disease and type 2 diabetes. The present invention also relates to a use of a recombinant vector or recombinant cell expressing a CREG protein or an active fragment thereof in manufacture of a medicament for the prevention and/or treatment of a fatty liver disease and type 2 diabetes. The invention also relates to a corresponding kit, such as a kit used for the predication and/or evaluation of therapeutic effect and prognosis of a fatty liver disease and type 2 diabetes.

Abstract: Preventing or reducing the symptoms of lactose intolerance in an animal comprising the consumption by the animal of a composition containing beta-casein, or providing the composition to the animal for consumption, where the beta-casein comprises at least 75% by weight beta-casein A2. The effect is both acute (post-exposure to the composition) and ongoing (future exposure to lactose).

Abstract: The present invention generally relates to uses of glial cell line-derived growth factor (GDNF) in cutaneous wound healing and hair growth. Methods of effecting hair growth and/or wound healing which feature administration of GDNF, or a biologically active fragment thereof, to subjects, e.g., human subject, are disclosed herein. The invention relates also to formulations and kits for achieving the indicated pharmaceutical advantages.

Abstract: A method for treating a patient suffering from an anti-HER2-resistant, MUC4+ HER2+ cancer is disclosed. For example, the method can be used to treat trastuzumab-resistant HER2+ breast cancer. In some embodiments, the method includes: (i) determining mucin-4 (MUC4) expression in cells of the patient; and (ii) if the MUC4 expression is greater than a predetermined-threshold, administering to the patient a therapeutically effective amount of a selective inhibitor of soluble tumor necrosis factor in combination with an anti-HER2 therapeutic agent, whereby said patient is treated.

Abstract: This disclosure relates to the field of therapeutic RNAs for treatment of solid tumor cancers.

Abstract: The invention relates to Interleukin 12 (IL12) or derivative thereof for use in the treatment of secondary infection. The present invention also relates to pharmaceutical composition comprising Interleukin 12 (IL12) or derivative thereof for use in the treatment of secondary infection. The present invention finds application in the therapeutic and diagnostic medical technical fields.

Abstract: The invention is concerned with a fusion protein, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and/or lymphoproliferation.

Abstract: The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.

Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.

Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Abstract: The invention relates to cyclic polypeptides derived from the C-terminus of acetylcholinesterase for use in treating or preventing cancer or metastatic disease.

Abstract: Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose-6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications.

Abstract: A co-therapeutic regimen comprising AAV9-mediated intrathecal/intracisternal and/or systemic delivery of an expression cassette containing a hIDUA gene and two or more immunosuppressants is provided herein. Also provided are methods useful for treating hIDUA deficiency (MPSI) and the symptoms associated with Hurler, Hurler-Scheie and Scheie syndromes.

Abstract: A method treats heel pain related to a compression of the medial/plantar nerve complex of the heel between the Quadratus Plantae and/or the Abductor Hallucis muscles. The method includes injecting a botulinum toxin into the insertional plantar fascia area of each of the Abductor Hallucis and Quadratus Plantae muscles in a foot of a patient having the heel pain.

Abstract: Disclosed are methods and compositions for treatment of a subject having a biliary disorder. The methods include administering a therapeutically effective amount of a serine protease inhibitor to a subject in need thereof. The biliary disorder may include biliary atresia, a biliopathy, Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC), and combinations thereof. In certain aspects, the serine protease inhibitor may be a protease inhibitor rC1 Inhibitor.

Abstract: A therapeutic composition including antithrombin gamma for diffuse intravascular coagulation or disseminated intravascular coagulation involving a decrease of antithrombin, or for thrombophilia due to congenital antithrombin deficiency and a method of using the composition are disclosed.

Abstract: In one embodiment, the invention provides an HSV vector comprising a mutant gB and/or a mutant gH glycoprotein, where the viral envelope further comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type. In another embodiment, the invention provides an HSV vector comprising (a) a mutant gC and/or gD envelope glycoprotein which comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type; and (b) a mutant envelope glycoprotein other than gD.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Described herein is a reliable method for preparing a potent vaccine useful for immunotherapy comprising the step of cryopreserving a population of cells undergoing immunogenic cell death, and using such cells to activate dendritic cells for use in immunotherapy. In a specific embodiment, the method comprises cryopreserving cancer cells undergoing cell death, which can be used to prepare a pharmaceutical composition for immunotherapy against cancer.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: In certain embodiments, methods and compositions are provided for generating immune responses against tumor antigens such as antigens or epitopes of HER1, HER2/neu, HER3, HER4, or any combination thereof. In particular embodiments, there may be provided methods for constructing and producing recombinant adenovirus-based vector vaccines containing nucleic acid sequences encoding tumor antigens such as antigens or epitopes of HER1, HER2/neu, HER3, HER4, or any combination thereof, that allow for vaccinations in individuals with preexisting immunity to adenovirus.

Abstract: A peptide vaccine for cranial nerve disease, containing a peptide that induces cytotoxic T-cells (CTLs) against Vascular Endothelial Growth Factor Receptor (VEGFR)-1-expressing cells, or a peptide that induces CTLs against VEGFR-2-expressing cells.

Abstract: Disclosed herein are compositions and methods for treating and/or preventing cancer in dogs, and in particular, vaccines that treat and provide protection against tumor growth.